Is Elekta AB (publ) (EKTAY) a Buy, Sell, or Hold?
OTC : EKTAY
Elekta AB (publ)
$4.75 USD
$0.01 (0.17%)
- Volume
- 2.78K
- Average Volume
- 2.34K
- Market Capitalization
- $1.81B
- P/E Ratio
- -34.36
- Dividend Yield
- 5.16%
- Price Target
- Year High
- $6.93
- Year Low
- $4.35
- Day High
- —
- Day Low
- —
- Payout Ratio
- -$1.77
- Current Ratio
- $0.87
Company Overview
OTC
Jakob Just-Bomholt
Medical - Instruments & Supplies
Healthcare
EKTAY
4541
SE
USD
Liquidity Metrics
1.03
0.87
0.68
0.21
-1.77
Sales & Valuation
$16.39B
1.02
2.51
8.14
5.47
Profitability
-$1.29
-$509.74M
-3.10%
-0.81%
-6.37%
-1.93%
P/E Metrics
-34.36
-0.39
-0.39
Analyst Price Target & Rating
2/5
1 Analysts
%
Financial Health Scores
1.44
4/9
-$1.95B
$26.82B
$19.71B
$810.7M
Key Metrics (TTM)
$21.25B
1.27
12.16
0.87
-6.37%
5.87%
-2.90%
12.26%
188 days
Company Executives
| Name | Title |
|---|---|
| John Lapré | Chief Business Line Officer |
| Christina Raaschou | Chief Human Resources Officer |
| Kathy Pajari | Head of Corporate Communications |
| Jonas Bolander | Chief Legal Officer |
| Caroline Leksell Cooke | Senior Vice President & Head of Neuro Solutions |
| Laurent Leksell | Founder & Chairman |
| Jakob Just-Bomholt | Chief Executive Officer & President |
| Christopher Busch | Chief Product & Technology Officer |
| Hilma Nordquist | Global Sustainability Director |
| Mattias Thorsson | Vice President and Head of Corporate Communications & Public Affairs |
| Klara Eiritz | Chief Financial Officer |
| Peter Nyquist | Head of Investor Relations |
Poll Results
No votes yet today — be the first to share your view!
About Elekta AB (publ) (OTC:EKTAY) Stock
Elekta AB (publ) is a global medical technology company dedicated to developing and delivering advanced clinical solutions for the treatment of cancer and brain disorders. Its comprehensive portfolio includes innovative radiotherapy systems such as the Elekta Unity MR-Linac, the Elekta Harmony linear accelerator, Elekta Infinity for diverse patient radiotherapy requirements, and the Elekta Synergy digital accelerator for advanced image-guided radiation therapy. Specific solutions like Versa HD are available for managing brain metastases. The company also supplies crucial treatment management software, automated and integrated quality assurance tools, and hardware and software for motion management. Further augmenting its oncology offerings, Elekta provides MOSAIQ Plaza for integrated multi ... disciplinary cancer care and Elekta Axis Cloud for managed hosting. Within brachytherapy, key products include the image-guided Elekta Studio, the mobile ImagingRing CT scanner, Oncentra Brachy for streamlining repetitive tasks, the Elekta Flexitron afterloader for precise workflow execution, and specialized applicators like Venezia and Geneva for cervical cancer treatment. For neurological conditions, Elekta offers a suite of advanced radiosurgery and neurosurgery solutions. This includes the Leksell Gamma Knife series – Icon for personalized radiation treatment, Perfexion for neurosurgical applications, and Lightning for accelerated procedures. Its neurosurgery product line features the Leksell Vantage Stereotactic System for intracranial interventions and the Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. Founded in 1972, Elekta maintains its corporate headquarters in Stockholm, Sweden.
Elekta AB (publ) (EKTAY) Analyst/Investor Day Transcript
2026-06-17 19:02:09
Elekta AB (publ) (EKTAY) Analyst/Investor Day Transcript
Elekta AB (publ) (EKTAY) Q4 2026 Earnings Call Transcript
2026-05-28 08:14:29
Elekta AB (publ) (EKTAY) Q4 2026 Earnings Call Transcript
Elekta AB: Tricky, But With A Latent Upside
2026-05-19 10:58:29
Elekta AB (publ) is rated Buy with a 56 SEK ($6 ADR) price target, reflecting a 15% annualized return potential at 15x P/E. EKTAY's historical premium is no longer justified due to persistent earnings misses, slow growth, and margin challenges, but current valuation now offers upside. Recent improvements include a 300 bps EBIT margin rise, 4.3% yield with a 79% payout ratio, and positive book-to-bill and cash flow trends.
Frequently Asked Questions
-
What is the current Elekta AB (publ) (EKTAY) stock price?
-
Elekta AB (publ)(OTC:EKTAY) stock price is $4.75 in the last trading session. During the trading session, EKTAY stock reached the peak price of $6.93 while $4.35 was the lowest point it dropped to. The percentage change in EKTAY stock occurred in the recent session was 0.17% while the dollar amount for the price change in EKTAY stock was $0.01.
-
EKTAY's industry and sector of operation?
-
The OTC listed EKTAY is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
-
Who are the executives of EKTAY?
-
John Lapré | Chief Business Line Officer
Christina Raaschou | Chief Human Resources Officer
Kathy Pajari | Head of Corporate Communications
Jonas Bolander | Chief Legal Officer
Caroline Leksell Cooke | Senior Vice President & Head of Neuro Solutions -
How many employees does EKTAY have?
-
Number of EKTAY employees currently stands at 4541. EKTAY operates from Hagaplan 4, Stockholm, SD 103 93, SE.
-
Link for EKTAY official website?
-
Official Website of EKTAY is: https://www.elekta.com
-
How do I contact EKTAY?
-
EKTAY could be contacted at phone #46 8 58 72 54 00 and can also be accessed through its website. EKTAY operates from Hagaplan 4, Stockholm, SD 103 93, SE.
-
How many shares of EKTAY are traded daily?
-
The average number of EKTAY shares traded daily for last 3 months was 2.34K.
-
What is the market cap of EKTAY currently?
-
The market value of EKTAY currently stands at $1.81B with its latest stock price at $4.75